Literature DB >> 31680196

Visual pathways evaluation in Kearns Sayre syndrome: a diffusion tensor imaging study.

Maria Camilla Rossi-Espagnet1,2, Martina Lucignani3, Luca Pasquini4,5, Antonio Napolitano3, Stefano Pro6, Andrea Romano5,7, Daria Diodato8, Diego Martinelli9, Daniela Longo4.   

Abstract

PURPOSE: Kearns Sayre syndrome (KSS) is a mitochondrial disorder characterized by development of visual impairment. Electroretinogram (ERG) and visual evoked potentials are not able to provide topographical information of optic damage. The purpose of this study was to explore retrochiasmatic optic pathway alteration in KSS with diffusion tractographic analysis and to compare it with different tracts.
METHODS: DTI from 8 KSS subjects (14.7 years) and 10 healthy controls (HC) were acquired on a 3T scanner. Optic radiations (OR), optic tracts (OT), inferior frontooccipital fasciculus (IFOF) and corticospinal tract (CST) were reconstructed with probabilistic tractography. Fractional anisotropy (FA), apparent diffusion coefficient (ADC), radial (RD), and axial diffusivity (AD) were calculated, evaluating group differences. T test on diffusion parameters identified significantly different track portions among cohorts.
RESULTS: All patients had optic pathway alterations at electrophysiological examination. Significant lower FA were found in OT, IFOF, and CST of KSS group. RD was significantly higher in bilateral OR, IFOF, CST, and right OT, while ADC was higher in bilateral OR and CST. RD values were higher in the proximal and distal portion of OR bilaterally and in the distal portion of right OT, while widespread differences were found in IFOF and CST. No significant differences were found for AD. FA profiles analysis demonstrated significant differences between groups in several regions of OT, IFOF, and CST, while ADC assessment revealed spread differences in OR and CST.
CONCLUSIONS: DTI evaluation of retrochiasmatic tracks may represent a useful tool to topographically investigate retrochiasmatic visual impairment in KSS.

Entities:  

Keywords:  Diffusion tensor imaging; Kearns Sayre syndrome; Leukodystrophy; Mitochondrial disorders; Optic pathway

Mesh:

Year:  2019        PMID: 31680196     DOI: 10.1007/s00234-019-02302-0

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  24 in total

1.  Utility of multimodal evoked potential study and electroencephalography in mitochondrial encephalomyopathy.

Authors:  V Scaioli; C Antozzi; F Villani; M Rimoldi; M Zeviani; F Panzica; G Avanzini
Journal:  Ital J Neurol Sci       Date:  1998-10

2.  Retinitis pigmentosa, external ophthalmophegia, and complete heart block: unusual syndrome with histologic study in one of two cases.

Authors:  T P KEARNS; G P SAYRE
Journal:  AMA Arch Ophthalmol       Date:  1958-08

Review 3.  Diffusion tensor imaging: A biomarker of outcome in Krabbe's disease.

Authors:  Andrea Poretti; Avner Meoded; Ali Fatemi
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

4.  White matter consequences of retinal receptor and ganglion cell damage.

Authors:  Shumpei Ogawa; Hiromasa Takemura; Hiroshi Horiguchi; Masahiko Terao; Tomoki Haji; Franco Pestilli; Jason D Yeatman; Hiroshi Tsuneoka; Brian A Wandell; Yoichiro Masuda
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-25       Impact factor: 4.799

Review 5.  The genetics of mitochondrial disease.

Authors:  Ryan L Davis; Carolyn M Sue
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

6.  Diffusion tensor MRI as a biomarker in axonal and myelin damage.

Authors:  Wint Yan Aung; Soe Mar; Tammie Ls Benzinger
Journal:  Imaging Med       Date:  2013-10-01

Review 7.  Electroretinographic findings in retinitis pigmentosa.

Authors:  E L Berson
Journal:  Jpn J Ophthalmol       Date:  1987       Impact factor: 2.447

8.  Diffusion tensor imaging detects axonal injury and demyelination in the spinal cord and cranial nerves of a murine model of globoid cell leukodystrophy.

Authors:  A Alex Hofling; Joong Hee Kim; Corinne R Fantz; Mark S Sands; Sheng-Kwei Song
Journal:  NMR Biomed       Date:  2009-12       Impact factor: 4.044

9.  Loss of myelin-associated glycoprotein in kearns-sayre syndrome.

Authors:  Nichola Z Lax; Graham R Campbell; Amy K Reeve; Nobuhiko Ohno; Jessica Zambonin; Emma L Blakely; Robert W Taylor; Eduardo Bonilla; Kurenai Tanji; Salvatore DiMauro; Evelyn Jaros; Hans Lassmann; Doug M Turnbull; Don J Mahad
Journal:  Arch Neurol       Date:  2012-04

10.  Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation.

Authors:  Klaus Schmierer; Claudia A M Wheeler-Kingshott; Daniel J Tozer; Phil A Boulby; Harold G Parkes; Tarek A Yousry; Francesco Scaravilli; Gareth J Barker; Paul S Tofts; David H Miller
Journal:  Magn Reson Med       Date:  2008-02       Impact factor: 4.668

View more
  4 in total

1.  Viability of diffusion tensor imaging for assessing retro-chiasmatic involvement in Kearns-Sayre syndrome remains elusive.

Authors:  Josef Finsterer
Journal:  Neuroradiology       Date:  2019-12-06       Impact factor: 2.804

2.  Reply to: Viability of diffusion tensor imaging for assessing retrochiasmatic involvement in Kearns-Sayre syndrome remains elusive.

Authors:  Maria Camilla Rossi-Espagnet; Stefano Pro; Diego Martinelli; Daria Diodato; Antonio Napolitano; Daniela Longo
Journal:  Neuroradiology       Date:  2019-12-14       Impact factor: 2.804

3.  Spinal cord involvement in Kearns-Sayre syndrome: a neuroimaging study.

Authors:  Pasquini Luca; Guarnera Alessia; Rossi-Espagnet Maria Camilla; Napolitano Antonio; Martinelli Diego; Deodato Federica; Diodato Daria; Carrozzo Rosalba; Dionisi-Vici Carlo; Longo Daniela
Journal:  Neuroradiology       Date:  2020-07-22       Impact factor: 2.804

Review 4.  In Vivo Brain GSH: MRS Methods and Clinical Applications.

Authors:  Francesca Bottino; Martina Lucignani; Antonio Napolitano; Francesco Dellepiane; Emiliano Visconti; Maria Camilla Rossi Espagnet; Luca Pasquini
Journal:  Antioxidants (Basel)       Date:  2021-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.